Aubagio vs Kesimpta
Side-by-side cost comparison based on Medicare Part D data
Aubagio
Teriflunomide
Manufactured by Sanofi
Kesimpta
Ofatumumab
Manufactured by Novartis
Aubagio costs 60% less per claim than Kesimpta ($3,363.00 vs $8,425.00). A generic version of Aubagio is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Aubagio | Kesimpta |
|---|---|---|
| Avg Cost Per Claim | $3,363.00 | $8,425.00 |
| Total Medicare Spending | $1.3B | $1.6B |
| Total Beneficiaries | 34,000 | 22,000 |
| Total Claims | 386,000 | 186,000 |
| Annual Cost/Patient | $38,176.00 | $71,227.00 |
| Year-over-Year Change | -5.6% | +68.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Sanofi | Novartis |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Teriflunomide | Ofatumumab |
Aubagio vs Kesimpta: What the Data Shows
Aubagio (Teriflunomide) and Kesimpta (Ofatumumab) are both used to treat multiple sclerosis. Based on Medicare Part D data, Aubagio costs $3,363.00 per claim, which is 60% less than Kesimpta at $8,425.00 per claim.
Medicare spent $1.3B on Aubagio and $1.6B on Kesimpta. In terms of patient reach, Aubagio serves more beneficiaries (34,000 vs 22,000).
Year-over-year spending changed -5.6% for Aubagio and +68.4% for Kesimpta. Kesimpta saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Aubagio is cheaper at $3,363.00 per claim, compared to $8,425.00 for Kesimpta. That makes Aubagio about 60% less expensive per claim based on Medicare Part D data.
Yes, both Aubagio and Kesimpta are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Teriflunomide and generic Ofatumumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.3B on Aubagio covering 34,000 beneficiaries, and $1.6B on Kesimpta covering 22,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.